167 related articles for article (PubMed ID: 33830081)
1. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.
Shimomura I; Watanabe N; Yamamoto T; Kumazaki M; Tada Y; Tatsumi K; Ochiya T; Yamamoto Y
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830081
[TBL] [Abstract][Full Text] [Related]
2. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
3. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
5. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
Kobayashi K; Terai H; Yasuda H; Hamamoto J; Hayashi Y; Takeuchi O; Mitsuishi Y; Masuzawa K; Manabe T; Ikemura S; Kawada I; Suzuki Y; Soejima K; Fukunaga K
Biochem Biophys Res Commun; 2021 Jan; 534():1-7. PubMed ID: 33302159
[TBL] [Abstract][Full Text] [Related]
6. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
[TBL] [Abstract][Full Text] [Related]
8. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
9. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
10. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
[TBL] [Abstract][Full Text] [Related]
11. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
12. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
13. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
[TBL] [Abstract][Full Text] [Related]
14. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
[TBL] [Abstract][Full Text] [Related]
15. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
Son KH; Kim MY; Shin JY; Kim JO; Kang JH
Anticancer Res; 2021 Oct; 41(10):4807-4820. PubMed ID: 34593430
[TBL] [Abstract][Full Text] [Related]
17. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
18. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
Tian D; Tang J; Geng X; Li Q; Wang F; Zhao H; Narla G; Yao X; Zhang Y
Cancer Lett; 2020 Nov; 493():80-90. PubMed ID: 32814087
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
20. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
